|
|
|
|
| LEADER |
03023nmm a2200313 u 4500 |
| 001 |
EB000621656 |
| 003 |
EBX01000000000000000474738 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
140122 ||| eng |
| 020 |
|
|
|a 9781461317371
|
| 100 |
1 |
|
|a Revel, Michel
|e [editor]
|
| 245 |
0 |
0 |
|a Clinical Aspects of Interferons
|h Elektronische Ressource
|c edited by Michel Revel
|
| 250 |
|
|
|a 1st ed. 1988
|
| 260 |
|
|
|a New York, NY
|b Springer US
|c 1988, 1988
|
| 300 |
|
|
|a XXVIII, 366 p
|b online resource
|
| 505 |
0 |
|
|a I Clinical Uses in Infectious and Immune Diseases -- 1. Intranasal Interferons for Control of Respiratory Viral Infections -- 2. Interferon Therapy of Herpes Simplex Dermal Infections and Papillomavirus Condylomata -- 3. Interferon Therapy in Acute Viral Illnesses -- 4. Kaposi’s Sarcoma and AIDS: The Role of Interferons in Treatment -- 5. Use of Interferon in the Treatment of Subacute Sclerosing Panencephalities -- 6. Multiple Sclerosis: Clincial Trials with Interferons -- 7. The Promise of Interferon Therapy for Parasitic Diseases -- II Clinical Uses in Cancer -- 8. Interferon Treatment of Non-Hodgkin’s Lymphoma and Myeloma: A Model for Biotherapy -- 9. The Role of Interferon Alpha in the Treatment of Hairy Cell Leukemia (HCL) -- 10. Clinical Studies of Alpha and Gamma Interferons in Chronic Myelogenous Leukemia -- 11. Interferon Therapy of Chronic Lymphocytic Leukemia and Viral Infections in Leukemia Patients --
|
| 505 |
0 |
|
|a 12. Interferons in the Treatment of Metastatic Renal Cell Carcinoma -- 13. Interferons in Breast Cancer -- 14. Osteosarcoma Management and Interferon -- 15. Clinical Use of Interferons in the Treatment of Malignant Brain Tumors -- 16. Interferon Treatment of Neuro-Endocrine Tumors of Pancreas and Gut -- 17. The Role of Beta Interferon in the Treatment of Cervical Dysplasia -- 18. Interferons in Combination with Cytotoxic Modalities for Cancer Treatment -- III Biological Properties and Experimental Systems -- 19. Toxic Effects -- 20. Pharmacokinetics of Interferons and Practical Implications -- 21. Monitoring of Interferon Therapy by Assay of Interferon-Induced (2 ??5?) Oligo A Synthetase in Human Peripheral White Blood Cells -- 22. Interferon Studies in Non-Human Primates -- 23. Animal Model Systems to Evaluate the Antitumor Activity of Interferons -- 24. Effects ofPolynucleotides on Monkeys and Man --
|
| 505 |
0 |
|
|a 25. Delivery of Interferons to Target Cells by Monoclonal Antibodies: Potential for the Specific Targeting of Other Lymphokines -- 26. Immunomodulatory Actions of Interferons -- 27. Synergistic Actions of Interferons and Tumor Necrosis Factor
|
| 653 |
|
|
|a Virology
|
| 653 |
|
|
|a Immunology
|
| 653 |
|
|
|a Oncology
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b SBA
|a Springer Book Archives -2004
|
| 490 |
0 |
|
|a Developments in Medical Virology
|
| 028 |
5 |
0 |
|a 10.1007/978-1-4613-1737-1
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-4613-1737-1?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 579.2
|
| 082 |
0 |
|
|a 616.96
|